Sec Form 4 Filing - Sterling Louis III @ AMARIN CORP PLC\UK - 2023-07-21

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sterling Louis III 2. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [ AMRN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22 3. Date of Earliest Transaction (MM/DD/YY) 07/21/2023 (Street) BRIDGEWATER,, NJ08807 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 1.12 07/21/2023 A 284,598 ( 1 ) 07/21/2033 Ordinary Shares ( 2 ) 284,598 $ 0 284,598 D Stock Option (Right to Buy) $ 1.12 07/21/2023 A 167,411 ( 3 ) 07/21/2033 Ordinary Shares ( 2 ) 167,411 $ 0 167,411 D Restricted Stock Units ( 4 ) $ 0 07/21/2023 A 94,866 ( 5 ) ( 6 ) Ordinary Shares ( 2 ) 94,866 $ 0 94,866 D Restricted Stock Units ( 4 ) $ 0 07/21/2023 A 55,804 ( 7 ) ( 6 ) Ordinary Shares ( 2 ) 55,804 $ 0 55,804 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sterling Louis III C/O AMARIN PHARMA, INC. 440 US HIGHWAY 22 BRIDGEWATER,, NJ08807 X Signatures By: /s/ Tom Reilly, by power of attorney 07/21/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )In connection with the Reporting Person's initial appointment to the Issuer's board of directors, on July 21, 2023 the Reporting Person was granted a one-time option to purchase 284,598 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan") and the Non-Employee Director Compensation Policy, as revised in May 2023 (the "Policy"). This option shall vest and become exercisable in equal annual installments over three years from the date of the Reporting Person's initial appointment to the Issuer's board of directors. ( 2 )The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. ( 3 )On July 21, 2023, following the conclusion of the Issuer's annual general meeting of shareholders for 2023, the Reporting Person was granted an option to purchase 167,411 Ordinary Shares under the Plan and the Policy. This option shall vest and become exercisable upon the earlier of the one-year anniversary of the grant date and the annual general meeting of shareholders in such anniversary year. ( 4 )Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. ( 5 )In connection with the Reporting Person's initial appointment to the Issuer's board of directors, on July 21, 2023 the Reporting Person was granted a one-time grant of 94,866 RSUs under the Plan and the Policy. These RSUs vest in equal annual installments over three years from the date of the Reporting Person's initial appointment to the Issuer's board of directors. The RSUs are subject to deferred settlement upon the director's separation of service with the Issuer. ( 6 )Not applicable. ( 7 )On July 21, 2023, following the conclusion of the Issuer's annual general meeting of shareholders for 2023, the Reporting Person was granted an award of 55,804 RSUs under the Plan and the Policy. These RSUs vest in full upon the earlier of the one-year anniversary of the grant date and the annual general meeting of shareholders in such anniversary year. The RSUs are subject to deferred settlement upon the director's separation of service with the Issuer.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.